Q4 2022 Results

Company overview Financial review 2023 priorities Appendix Iptacopan - provides the opportunity to redefine care across multiple complement-driven conditions¹ INNOVATION 2021 2022 2023 2024 First-in-class, oral, selective factor B inhibitor, targeting complement system proximally via alternative pathway¹ Indication 2025 2026+ Key updates US prevalence Thousands PNH Ph3 - APPLY Ph3-APPOINT Superior to SoC for both primary endpoints in patients with residual anemia despite SoC Achieved clinically meaningful increases in Hb levels in treatment-naive patients with PNH <10 IgAN Ph3 - APPLAUSE C3G Ph3 APPEAR aHUS IC-MPGN * 9 months analysis (H2 2023) potentially provides basis for US Subpart H filing on proteinuria reduction Submission enabling readout H2 2023 1852 <10 Ph3 APPELHUS Submission enabling readout in 2025 <10 Ph3 Ph3 start in H2 2023 <10 Additional ongoing early-stage (Ph2) activities in Lupus Nephritis, iAMD and Immune thrombocytopenia PNH - paroxysmal nocturnalhemoglobinuria. IgAN - immunoglobulin A nephropathy. C3G complement 3 glomerulopathy. aHUS atypical hemolytic uremic syndrome. iAMD - intermediate age-related macular degeneration. IC-MPGN - immune complex membranoproliferative Glomerulonephritis. *9 months readout may support US submission for accelerated approval. 1. Phase 3 studies initiated or planned; additional indications are being explored. 2. Estimated ~46-55k number of patients at high risk of progression with proteinuria > 1g/day (~25-30%). 16 Investor Relations | Q4 2022 Results ✓ NOVARTIS | Reimagining Medicine

View entire presentation